Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
I-MAB ( (IMAB) ) has provided an update.
On August 22, 2025, I-Mab announced the appointment of Dr. Robert Lenz and Ms. Xin Liu as independent members of its Board of Directors, with Ms. Liu also joining the Audit Committee. The company also formed a Research and Development Committee, chaired by Dr. Lenz, to drive innovation and growth. Additionally, Dr. Ken Takeshita was appointed to the Scientific Advisory Board. The changes aim to strengthen I-Mab’s strategic focus on research and development excellence and enhance its leadership in the biotech industry.
The most recent analyst rating on (IMAB) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on I-MAB stock, see the IMAB Stock Forecast page.
Spark’s Take on IMAB Stock
According to Spark, TipRanks’ AI Analyst, IMAB is a Neutral.
The overall stock score of 45 reflects I-MAB’s substantial financial challenges, particularly in terms of profitability and cash flow generation, which heavily impact its financial performance. Despite a modest technical uptrend, valuation metrics point to significant risks, with ongoing losses and a negative P/E ratio limiting its appeal. The absence of recent earnings call data or notable corporate events further solidifies the overall cautious outlook.
To see Spark’s full report on IMAB stock, click here.
More about I-MAB
I-Mab is a U.S.-based global biotech company focused on developing precision immuno-oncology agents for cancer treatment. The company’s pipeline is led by givastomig, a bispecific antibody designed to treat Claudin 18.2-positive gastric cancers, with potential applications in other solid tumors.
Average Trading Volume: 2,008,400
Technical Sentiment Signal: Buy
Current Market Cap: $403.1M
See more insights into IMAB stock on TipRanks’ Stock Analysis page.